Los Angeles, CA, May 02, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced the appointment of Nevena Zubcevik, DO, MSPT, ATC as its chief medical officer starting July 1, 2019.
In her new role, Dr. Zubcevik will be in charge of medical and clinical strategy, including development and regulatory matters and new business development. That role will be increasingly important as Endonovo continues to develop its PEMF assets and the national roll-out of SofPulse.
Dr. Zubcevik has over 24 years experience in the medical field, 17 of which are in clinical development, and is a licensed physician and educator. Prior to Endonovo, Dr. Zubcevik was an Attending Physician at Harvard Medical School/Partners HealthCare in the Physical Medicine and Rehabilitation Department. During her tenure at Harvard, Dr. Zubcevik was involved in innovation in both the clinical and research arenas, serving as a Principal Investigator to clinical trials and Clinical co-Director. She was also an Executive Director at LIV NGO, a non-profit organization.
“Nevena’s broad expertise and proven track record as a physician and her experience in global clinical development will be invaluable to Endonovo as we continue to advance our pipeline of products and treatments,” Endonovo CEO Alan Collier stated. “Nevena has a number of publications and has been a speaker and presenter at medical conferences that date back to 2000. Her experience, contacts and knowledge of our market is unprecedented and it is with great pleasure that I welcome Nevena as our chief medical officer to the Endonovo family.”
“It is a privilege to join the Endonovo team,” commented Dr. Zubcevik. “I look forward to advancing the PEMF assets which improve the quality of life for postoperative patients. Over the last few months I’ve witnessed firsthand Endonovo’s incredible growth trajectory and the market’s validation of the company’s FDA cleared SofPulse product and am looking forward to growing the clinical applications of this fantastic technology as we combat the opioid epidemic.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com